Project Grant HT94252510224
Award Date
4/15/25
Completion Date
4/14/29
Dollars Obligated
$1.6M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
This federal Project Grant award of $459,747.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research at the University of Wisconsin-Madison to define the effect of copy number amplification on the regulation of oncogenes in high-grade serous ovarian carcinoma. The research will examine the contributions of superenhancers at the 8q22 region, with the goal of advancing scientific understanding and potential treatment...
This Project Grant award for $699,750 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to the University of Washington aims to support the discovery and characterization of tissue-specific regulatory mutations that predispose to ovarian cancer. The award will fund research activities over a 3-year period from April 2024 to March 2027. As a leading research university, the University of Washington has extensive experience managing federal grants and...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $155,500.00 to the University of Wisconsin - Madison to develop a model to study tumor-normal cell interaction in vitro for high-throughput drug screening. The award period runs from December 1, 2024 to November 30, 2025. This grant supports innovative biomedical research focused on transforming healthcare for military service members and the...
This federal Project Grant award, valued at $785,833.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports research targeting immunotherapy-resistant lesions to eradicate oligometastatic prostate cancer, with a performance period from September 1, 2024 to August 31, 2027. The primary awardee is the University of Wisconsin System, specifically the University of Wisconsin-Madison's Research and Sponsored Programs...
This federal Project Grant award of $1,146,270.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Wisconsin System. The grant supports research targeting a lipid kinase regulator of nuclear AKT in breast cancer, with a performance period from July 15, 2023 to July 14, 2026. The University of Wisconsin System, through its University of Wisconsin - Madison division, will conduct this biomedical research to...
The federal Project Grant award of $932,918 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is supporting research at the University of Washington to determine the role of somatic mosaicism in ovarian cancer predisposition. The grant, awarded on September 30, 2024 with an ultimate completion date of September 29, 2028, will enable the University of Washington to conduct innovative scientific studies to improve health outcomes for military...
This federal Project Grant award, with a total funding amount of $592,859.00, was provided by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant supports advanced cancer research at the University of Wisconsin-Madison, focusing on gene expression analysis of circulating tumor cells as a next-generation biomarker to predict immunotherapy response in metastatic clear cell renal cell carcinoma. The project aims to...
This $516,366 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program supports research to target immunotherapy-resistant lesions and eradicate oligometastatic prostate cancer. The 3-year award to the University of Wisconsin System, with a performance period from September 1, 2024 to August 31, 2027, will fund innovative approaches to advance the treatment and management of prostate cancer, a significant health...
This $1,146,270 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Wisconsin System to target a lipid kinase regulator of nuclear Akt in breast cancer. The project aims to transform health care for Service Members and the American public through innovative and impactful research, with a focus on medical solutions for the battlefield. The grant will fund research activities at the University of...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $467,742 Project Grant to the Regents of the University of Michigan to optimize a risk stratification model for ovarian cancer. The award will support research activities from September 1, 2024 through August 31, 2026. The University of Michigan, a top public research institution, has extensive experience conducting federal research and development projects for agencies such as the...